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Major Depressive Disorder 
Dr Arlene BONELLO 
Depression in its various forms is a commonly seen disorder in general practice. 
Indeed, over 90% of patients sufferingfrom depression are seen, diagnosed and treated 
in primal) care. The most severe, cl1rGnic and complicated cases are referred 011 to a psychiatrist. 
Background 
The World Health Organization (WHO) predicts that by 
2020, depression will become the second leading cause of 
disability adjusted life-years lost worldwide, after ischaemic 
heart disease. About 20 per cent of the population will develop 
a depressive episode at some point in their lives, with up to 85 
per cent of patients having more than one episode. Further, one 
in 10 patients with depression will commit suicide, and up to 
20 per cent of patients wlth depression will have symptoms for 
two years or more (chronic depression) l 
General practitioners are immensely variable in their ability 
to recognize depressive illnesses, with some recognizing virtually 
all the patients found to be depressed at independent research 
interview, and others recognizing very few. The communication 
skills of the GP make a vital contribution to detennining their 
ability to detect emotional distress, and those wlth superior skills 
allow their patients to show more evidence of distress dUling 
their interviews, thus making detection easy. Those doctors with 
poor communication skills are more likely to collude with their 
patients, who may not themselves wish to complain of their 
distress unless they are asked directly about it. 2 
Those patients with more severe disorders, and those 
presenting psychological symptoms to their doctor, arc especially 
likely to be recognized as depressed, while those presenting with 
somatic symptoms for which Jio cause can be found are less likely 
to be recognized. 1 
Pathophysiology 
The underlying pathophysiology of major depressive disorder 
(M DD) has not been clearly defined. Clinical and preclinical trials 
suggest a disturbance in CNS serotonin (i.e, 5-HT) acti\~ty as 
an important factor. Other neurotransmitters implicated include 
norepinephline (NE) and dopamine (OA) 
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The role of CNS serotonin activity in the pathophYSiology of 
MOD is suggested by the efficacy of selective serotonin reuptake 
inhibitors (SSRls) in the treatment of MOD. Furthermore, 
studies have shown that an acute, transient relapse of depressive 
symptoms can be produced in research subjects in remission 
using tryptophan depletion, which causes a temporary reduction 
in CNS serotonin levels. Serotonergic neurons implicated in 
affective disorders are found in the dorsal raphe nucleus, the 
limbic system, and the left prefrontal cortex. 4 
Clinical experience indicates a complex interaction between 
neurotransmitter availability, receptor regulation and sensitivity, 
and affective symptoms in MOD . Drugs that produce only an 
acute Jise in neurotransmitter availability, such as cocaine, do 
not have efficacy over time as antidepressants. Furthermore, an 
exposure of several weeks' duration to an antidepressant usually is 
necessary to produce a change in symptoms. This, together with 
preclinical research findings, implies a role for neuronal receptor 
regulation over time in response to enhanced neurotransmitter 
availability. 
All available antidepressants appear to work \~a 1 or more of 
the follo\ving mechanisms: (l) presynaptic inhibition of uptake 
of 5-HT or NE; (2) antagonist acti\~ty at presynaptic inhibitory 
5-HT or NE receptor sites, thereby enhancing neurotransmirter 
release ; or (3) inhibition of monoamine oxidase, thereby redUCing 
neurotransmitter breakdown. j 
Symptoms 
Depression refers to a \Vide range of mental health problems 
characterized by the absence of a positive affect (a loss of interest 
and enjoyment in ordinary things and cxpeJiences), low mood 
and a range of associated emotional, cognitive, physical and 
behavioural symptoms . Distinguishing the mood changes 
between major depreSSion and those occurring 'normally' 
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remains problematic: persistence, severi ty, the presence of other 
symptoms and the degree of functional and social impainnent 
fonn the basis of that distinction 
Commonly, mood and affect in a major depressive illness 
are unreactive to circumstance, remaining low throughout the 
course of each day, although for some people mood varies 
diurnally, with gradual improvement throughout the day only 
to return to a low mood on waking. A person's mood may be 
reactive to positive experiences and events, although these 
elevations in mood are not sustained, with depressive feelings 
re-emerging, often quickly 
Behavioural and physical symptoms typically include 
tearfulness, irritability, social \vithdrawal, reduced sleep, an 
exacerbation of pre-existing pains, and pains secondary to 
increased muscle tension and other pains," lowered appetite 
(sometimes leading to significant weight loss) , a lack of libido, 
fatigue and diminished activity, although agitation is common 
and marked anxiety frequent. Along wi th a loss of interest and 
el~oyment in everyday life, feelings of guilt, worthlessness and 
deserved punishment are common, as are lowered self-esteem, 
loss of confidence, fee lings of helplessness, suicidal ideation 
and attempts at self-harm or suicide. Cognitive changes include 
poor concentration and reduced attention, pessimistic and 
recurrently negative thoughts about oneself, one's past and the 
future, mental slowing and rumination l 
Diagnosis 
In order to diagnose depreSSive illness, diagnostic 
classifications such as the 'International classification of 
diseases' 10th edition (lCD- 10) and the 'Diagnostic and 
statistical manual of mental disorders' 4th edition (DSM-IV), 
an American system, have been developed. In both these 
classifications (see below) , a diagnosis of depreSSion is made 
from the presence of a number of specific symptoms, or a 
syndrome, for a minimum of two weeks . It therefore relies on 
one of the most fundamental medical skills, that of recognizing 
patterns of symptoms. The two systems differ in that ICD-lO 
provides guidelines in making a diagnosis, whereas 
DSM-IV ismore explicit in the symptoms required to make 
a diagnosis. However, both systems allow the coding of 
somatic symptoms, psychotiC symptoms, and other illness 
characteristics. 
The ICD·10 Classification System 
for Depression 
Classification Symptoms of a Depressive Episode. 
Typical Features for a Period of Around Two Weeks: 
• Depressed mood 
• Loss of interest and enJo)'lllent 
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• Reduced energy or increased tiredness 
• Reduced activity 
Other Common Symptoms: 
• Reduced concentration and attention 
• Reduced self-confidence and self-worth 
• Guilt and unworthiness 
• Bleak and pessimistic regarding the future 
• Self-harm or suicidal ideas 
• Disturbed sleep 
• Reduced appetite 
Somatic Symptoms: 
Low mood may vary over the course of the day 
Motor activity may be slowed or increased 
Sexual appetite my be reduced 
Patient may lose weight 
Loss of interest and unreactivity of mood may be present 
PsychotiC symptoms (usually hallucinations or delusions) 
may be present in severe depression. Determination of the severity 
of depression is based upon a clinical judgement involving the 
number, type and severity of symptoms. 
Diagnostic Guidelines 
F32.0 Mild Depressive Episode 
The presence of at least two of the typical symptoms of 
depreSSion plus at least two of the other symptoms. None of the 
symptoms should be present to an intense degree. Minimum 
duration of the whole episode is about 2 weeks . An individual 
with a mild depreSSive episode is usually distressed by the 
symptoms and has some difficulty in continuing with ordinary 
work and social activities, but will probably not cease to function 
completely. 
A fifth character may be used to specify the presence 
of the somatic syndrome: 
F32.00 Without Somatic Symptoms 
The criteria for mild depreSSive episode are fulfilled, and there 
are few or none of the somatic symptoms present. 
F32.01 With Somatic Symptoms 
The criteria for mild depressive episode are fulfilled , and four 
or more of the somatic symptoms are also present. (If only two 
or three somatic symptoms are present but they are unusually 
severe, use of this category may be Justified) . 
Moderate Depressive Episode 
The presence of at least two of the three most typ ical 
synlptoms noted for mild depressive episode should be present, 
plus at least three and preferably four of the other S)mlptoms. 
Several sytnptoms are likely to be present to a marked degree, but 
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this is not essential if a particularly wide variety of symptoms is 
present overall. The minimum duration of the whole episode is 
about 2 weeks . An individual with a moderately severe depressive 
episode will usually have considerable difficulty in continuing 
with social, work or domestic activities. A fifth character may be 
used to speci~1 the occurrence of somatic symptoms: 
F32.10 Without Somatic Symptoms 
The cri telia for moderate depressive episode are fulfilled, and 
few if any of the somatic symptoms are present. 
F32.11 With Somatic Symptoms 
The criteria for moderate depressive episode are fulfill ed, and 
four or more or the somatic symptoms are present. (If only tvvo 
or three somatic symptoms are present but they are unusually 
severe, use of this category may be justified) . 
Severe Depressive Episode 
All three of the typical symptoms noted for mild and 
moderate depressive episodes should be present, plus at least four 
other symptoms, some of which should be of severe intensity. 
However, if important symptoms such as agitation or retardation 
are marked , the patient may be unwilling or unable to desclibe 
many symptoms in detail. An overall grading of severe episode 
may still be Justified in such instances. The depressive episode 
should usually last at least 2 weeks, but if the symptoms are 
particularly severe and of very rapid onset, it may be justified 
to make this diagnosiS after less than 2 weeks. DUling a severe 
depreSSive episode it is very unlikely that the sufferer wi ll be able 
to continue wi th social, work, or domestic activities, except to 
a very limited extent. 
Severe Depressive Episode 
with Psychotic Symptoms 
A severe depreSSive episode which meets the critelia given 
for severe depressive episode without psychotiC symptoms and in 
which delusions, hallucinations, or depressive stupor are present. 
The delusions usually involve ideas of sin , poverty, or imminen t 
disasters, responSibility for which may be assumed by the patient. 
Auditory or olfactory hallucinations are usually of defamatory or 
accusatory yoices or of rotting filth or decomposing Oesh. Severe 
psychomotor retardation may progress to stupor. If required , 
delusions or hallucinations may be speCified as mood-congruent 
or mood-incongruent. ~ 
DSM-IV Diagnostic Criteria 
a. A minimum of five symptoms from the following list have 
been present during the same 2-week peliod and represent 
a change from previous functioning. One of the symptoms 
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must be 1 or 2, as listed below 1) Depressed mood most 
of the day, nearly every day, as indicated either by subjective 
report (e.g. feels sad or empty) or observation made by 
others (e.g. appears tearful) 2) Markedly diminished interest 
or pleasure in all , or almost all, activities most of the day, 
nearly every day, as indicated ei ther by subjective account 
or observation made by others. Do not include symptoms 
that are clearly due to general medical condition or mood-
incongruent delusions or hallucinations 3) Significant weight 
loss when not dieting or weight gain (e .g. a change of more 
than 5% of body weight in a month) or decrease or increase 
in appetite nearly every day 4) Insomnia or hypersomnia 
nearly every day 5) Psychomotor agitation or retardation 
nearly every day (observable by others, not merely subjective 
feelings of res tlessness or being slowed down) 6) Fatigue or 
loss of energy nearly every day 7) Feelings of worthlessness 
or excessive or inappropliate guilt (which may be delusional) 
nearly every day (not merely self-reproach or guilt about 
being sick) 8) Diminished ability to think or concentrate, 
or indecisiveness, nearly every day (ei ther by subjective 
account or as observed by others) 9) Recurrent thoughts 
of death (not just fear of dying), recurrent suicidal ideation 
without a speCific plan, or a suicide attempt or specific plan 
for committing suicide 
b. The symptoms do not meet the criteria 
for a mixed episode 
c. The symptoms cause clinically significant distress or 
impainnent in social, occupational, or other important areas 
of functioning 
d. The symptoms are not due to the direct physiological effects of 
a substance (e.g. , a drug of abuse, a medication) or a general 
medical condi tion (e.g., hypothyroidism) 
e. The symptoms are not better accounted for by bereavement, 
i. e., after the loss of a loved one, the symptoms persist 
for longer than 2 months or are characterized by marked 
fu nctional impairme nt , morbid preoccupation wi th 
worthlessness, suicidal ideation, psychotiC symptoms, 
or psychomotor retardation. <) 
Differential Diagnosis 
The differential diagnosis in patients presenting,vith alterations 
in mood is extensive and should include consideration 
of the follOwing: 
1. Personality disorders: Certain personality disorders (e.g., 
borderline personality disorder) may present with mood 
changes as a prominent symptom . The presence of a 
personality disorder can be difficult to determine in the 
setting of acute affective symptoms. Many patients who are 
depressed who appear labile , demanding, or patholOgically 
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dependent look dramatically different once the depressive 
episode has been treated adequately 10 
2. Mood disorders secondary to CNS conditions: These include 
a broad range of physiologic and structural CNS processes 
that can produce changes in mood and behaviour. Major 
Depressive Disorder (MDD) can produce measurable 
cognitive deficits or a worsening of preexisting dementia. 
This decline in cognitive functioning, which, on formal 
testing, appears to arise from impaired concentration or 
motivation, is referred to as dementia of depression and 
should remit with successful treatment of the depreSSive 
episode. MDD does not cause focal neurological signs. 
Such findings should prompt an evaluation for other organic 
syndromes. 
3. Alzheimer disease: This disease and other degenerative 
and vascular dementias can be associated with affective 
symptoms. Mood disorders are very prominent in Parkins on' s 
disease, Huntington's disease, multiple sclerosis, stroke, and 
seizure disorders . 5 
4. Neoplastic lesions of the CNS: These lesions also can cause 
changes in mood and behaviour before the onset of focal 
neurological signs. 
5. Inflammatory conditions: Conditions such as systemic lupus 
erythematosus (SLE) can produce a wide range 
of neuropsychiatric signs and synlptoms, likely because 
of alterations in the blood-brain barrier 
and an autoimmune cerebritis. 
6. Sleep disorders: Obstructive sleep apnea, espeCially, can 
cause Significant medical and psychianic symptoms and 
often is missed as a diagnosis. Patients, and, if necessary, 
their partners, should be interviewed regarding their sleep 
quality, daytime sleepiness, and snoring. Polysomnography 
can help make the diagnosis and guide treatment. 
7. Infectious processes These include syphilis, Lyme disease, 
and HIV encephalopathy, which can cause mood 
and behavior changes. 
8. Pham1acologic agents: Substances that can produce changes 
in mood include antihypertensive medications (espeCially 
beta-blockers, reserpine, methyldopa, and calcium channel 
blockers); steroids; medications that affect sex honnones 
(e .g., estrogen, progesterone, testosterone, gonadotropin-
releasing hormone [GnRH] antagonists); H2 blockers (e.g., 
ranitidine, cimetidine); sedatives; muscle relaxants; appetite 
suppressants; and chemotherapy agents 
(e.g., vincristine, procarbazine, L-asparaginase, interferon, 
amphotelicin B, vinblastine) 
9. Endocrinologic disorders: Disorders involVing the 
hypothalamic-pituitary-adrenal axis or thyroid are espeCially 
likely to produce changes in mood. These include 
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Addison disease, Cushing disease, hyperthyroidism , 
hypothyroidism, 
prolactinomas, and hyperparathyroidism. 
10. Substance use, abuse, or dependence: These can cause 
significant mood symptoms. This is especially true of 
alcohol, cocaine, amphetamines, marijuana, sedatives/ 
hypnotics, and narcotics. Inhalant abuse also should be 
considered, particularly among young male patients. Other 
substance-related and psychiatric processes either can 
present with mood disturbance as the primary symptom 
or can occur together with MDD . 
11. Dysthymia This mood disorder presents with low mood as 
a primary symptom. Dysthymia can predate a depressive 
episode. The symptoms of dysthymia alone do not meet 
criteria for MDD and must be present for at least 2 years. 
12. Anxiety disorders: Patients vvith anxiety disorders are at 
higher risk for developing comorbid depression. In such 
patients, it is important to identify the anxiety disorder 
because they often require specific treatment approaches. 
Commonly encountered anxiety disorders include panic 
disorder, obsessive-compulsive disorder, generalized anxiety 
disorder, posttraumatic stress disorder, and phobia. 
13 Eating disorders: People with eating disorders (EDs) also 
have a high rate of comorbid MDD and require speCific 
treatment approaches. These disorders include bulimia, 
anorexia nervosa, and ID not otherwise specified 5 
14. Bereavement: Depressed mood, disturbed sleep, and crying 
occur in over 50 per cent of bereaved subjects, but there is 
no disturbance of self-esteem. However, about one-third 
of the subjects have feelings of guilt concerning the dead 
person. I I 
15. Schizophrenia: Patients with schizophrenia may develop 
pronounced depressive symptoms . Persistent non-
affective delusions or hallucinations, and even depressive 
hallucinations that are continuous rather than occasional, 
suggest schizophrenia. II 
Aetiology 
Depression is a broad and heterogenous psychianic disorder 
that affects people of all ages, from childhood to old age. It varies 
in severity and duration, and there is a difference in incidence 
between sexes, being more common in women with a prevalence 
twice that observed in men. Boys and girls are affected equally 
It is unlikely that there is only one cause of depression. Rather, 
its aetiology is multifactorial. 
Aetiology can be divided into predisposing, personality and 
provoking factors. 
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Predisposing Factors Management 
Genetic influence: It has been recognized for over 50 years A wide range of effective treatments is available for depressive 
that mental disorders , including mood disorders, aggregate disorder. Brief psychotherapy (e.g., cognitive behavioral therapy 
in families. By means of t\vin studies and studies of adopted (CBT), interpersonal therapy) has been shown in clinical trials to 
children, the genetic contribution to affective disorders has been be an effective treatment option, either alone or in combination 
established. In t\vin studies, for example, concordance is 80 per with medication . Medication alone also can relieve symptoms. 
cent for bipolar disorders and 60 per cent for recurrent depression. However, the combined approach generally provides the patient 
Early childhood environment Challenges are faced in trying to with the quickest and most sustained response. 
identify the influence of an individual's early life experiences on 
his or her predisposition to affective disorders. For example, much 
research has been carried out on inves tigating the importance of 
the parent-child relationship. Clear evidence suggests that lack 
of adequate paren tal care may be a developmental risk factor 
for adult depression. Many studies have also shown that early 
bereavement - especially loss of mother by death or separation-
makes people more vulnerable to later loss experiences. An 
influential study by Brown et al argued that the loss of the mother 
before the age of 11 years was associated with a greater risk of 
adult depreSSion, suggesting a direct causal link. 12 Maternal over 
- protection has also been incriminated in several studies in which 
depressed patients remembered their childhoods. 
Personality Factors 
Those who develop depreSSive illnesses are more likely to 
have low self - esteem and are rather more likely to be introverted 
and obsessional. Low self - esteem greatly increases the risk of a 
depreSSive illness following a stressful life event . Negative views 
about oneself, one's future and one's surroundings are said to 
constitute the "cognitive triad" which renders people vulnerable 
to depressive illness. 1 1 
Provoking Factors 
Loss events may be the loss of a relationship, bereavements, 
threatened future losses or even failure to be promoted. These 
are especially likely to precipitate depression in those with low 
self - esteem. The loss may precede the episode of depression 
by as much as one year. 
Physical illness commonly contributes to the genesis of 
depressive illnesses seen in general medical settings. For example 
illnesses as stroke, a heart attack cancer, Parkinson's disease, and 
hormonal disorders can cause depressive illness, making the sick 
person apathetiC and umvilling to care for his or her physical 
needs, thus prolonging the recovery period. 
Stressful social circumstances such as having unsatisfactory 
living conditions, poor interpersonal relationships and very 
little social support can favour the release of depressive 
phenomena. I 1 
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Mild Depressive Episode 
The large majority of patients ,vith depreSSion are cared for 
solely in primary care. 
For a Significant number of people with mild to moderate 
depression, brief interventions delivered by the primary care team 
are effective; for others - particularly if they have not responded to 
the initial brief intervention - more complex interventions, which 
could be provided in primary or secondary care, are reqUired. 
Many patients with milder depression respond to interventions 
such as exercise e.g. advice is given to follow a supervised and 
structured exercise programme of approximately 45 minutes three 
times a week for a period of 10 to l 2 weeks. 
Guided self-help, although many improve while being 
monitored ,vithout additional help , may be beneficial. More 
structured therapies, such as problem-solving, brief Cognitive 
Behavioural Therapy (CBI) or counselling can be helpful. 
Antidepressant drugs and psychological therapies, such as 
longer-term CBT or interpersonal psychotherapy (lPT), are not 
recommended as an initial treatment; these may be offered when 
simpler methods (for example, guided self-help or exercise) have 
failed to produce an adequate response. 
Antidepressants are not recommended for the initial treatment 
of mild depression, because the risk- benefit ratio is poor. 
The use of antidepressants should be considered for 
patients : 
• with mild depreSSion that is persisting after other 
interventions. 
whose depression is associated with psychOSOCial 
and medical problems. 
\vith a past history of moderate or severe depression present 
,vith mild depression ll 
Moderate or Severe Depressive Episode 
In moderate or severe depression, the choice of treatment 
will reflect patient preference, past expelience of treatment and 
the fact that the patient may not have benefited from other 
interventions as explained above. 
With more severe depreSSion, the risk of suicide should 
always be considered. Referral to secondary senices should be 
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based on this assessment, the degree of functional impairment and low toxicity in overdose. Common adverse effects include 
and the presence of significant comorbidities or speCific GI upset, sexual dysfunction, and changes in energy level (ie, 
symptoms fatigue, restlessness) j 
Where a patient presents considerable immediate risk to Selective Serotonin/Norepinephrine Reuptake 
self or others, for example patients with symptoms of psychotic Inhibitors 
depression, urgent referral for specialist treatment should be (SNRls) include venlafaxine and duloxetine. Safety, tolerability, 
arranged.il and side effect profiles are similar to that of the SSRIs, with the 
Antidepressant Drugs 
There is more evidence for the effectiveness of antidepressant 
medication in moderate to severe depression than in milder 
depression. Careful monitoring of symptoms, side effects and 
suicide 11sk (particularly in those aged under 30) should be 
routinely undertaken, espeCially when initiating antidepressant 
medication. It is also important to monitor patients for relapse 
and withdrawal symptoms when redUCing or stopping medication 
and they should be warned about the risks of redUCing or 
stopping medication. Treatment failures often are caused not by 
clinical resistance, but by medication noncompliance, inadequate 
duration of therapy, or inadequate dosing. 
exception that the SNRIs have been associated (rarely) with a 
sustained rise in blood pressure. SNRls can be used as first-line 
agents, particularly in patients with Significant fatigue or pain 
syndromes associated with the episode of depression. The SNRIs 
also have an important role as second-line agents in patients who 
have not responded to SSRls ' 
Atypical Antidepressants include bupropion, nefazodone, 
mirtazapine, and trazodone. This group also shows low toxicity 
in overdose and may have an advan rage over the SSRls by causing 
less sexual dysfunction and GI distress. 
Bupropion is associated with a risk of seizure at higher 
doses, espeCially in patients with a history of seizure or eating 
disorders . 
Mirtazapine is a potent antagonist at 5-HT2, 5-HTJ, alpha2-, 
and histamine (Hl) receptors and, thus, can be very sedating. 
Adverse effects such as drowsiness and weight gain may tend to 
improve over time and with higher doses. 
Trazodone is very sedating and usually is used as a sleep aid 
rather than as an antidepressant. 
Monoamine Oxidase Inhibitors (MAO Is) include phenelzine 
and tranylcypromine. 
MAOIs are widely effective in a broad range of affective and 
anxiety disorders. However they are potentially toxic drugs and 
side effects are common. 
Patients started on antidepressants who are not considered 
to be at increased risk of suicide should normally be seen after 
two weeks . Thereafter they should be seen on an appropriate 
and regular basis, for example, at intervals of two to four weeks 
in the first three months and at longer intervals thereafter, if 
response is good. Antidepressants should be continued for at 
least six months after remission of an episode of depreSSion, 
because this greatly reduces the risk of relapse. When a patient has 
taken antidepressants for six months after remission, healthcare 
professionals should review with the patient the need for 
continued antidepressant treatment. This review should include 
consideration of the number of previous episodes, presence of 
residual symptoms, and concurrent psychosocial difficulties. i 1 
Because of the 11sk of hypertenSive clisis, patients on these 
medications must follow a low-tyramine diet. Other adverse 
effects can include insomnia, anxiety, onhostasis, weight gain, 
Tricyclic Antidepressants (TCAs) include amitriptyline, and sexual dysfunction ' 
nortriptyline, desipramine, clomipramine, doxepine, proniptyline, 
nimipramine, and imipramine. 
This group has a long record of efficacy in the treatment 
of depreSSion and has the advantage of lower cost. The 
disadvantages include the need to titrate the dose to a therapeutiC 
level and considerable tol-icity in overdose. 
Adverse effects largely are due to their anticholinergiC and 
antihistaminic properties and include sedation, confusion, dry 
mouth, orthostasis, constipation , urinary retention, sexual 
dysfunction, and weight gain. Caution should be used in patients 
with cardiac conduction abnormalities .5 
Selective Serotonin Reuptake Inhibitors (SSRls) include 
fluoxetine, paroxetine, senraline, fluvoxamine, citalopram, and 
escitalopram. This group has the advantage of ease of dosing 
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Non Pharmacologic Treatment 
Electroconvulsive Therapy (ECT) involves the induction 
of a modified epileptiC seizure given through electrodes placed 
bitemporally or vvith both on the non-dominant hemisphere. 
It is a highly effective treatment for depreSSion and may have a 
more rapid onset of action than drug treatments . Advances in 
brief anaesthesia and neuromuscular paralysis have improved 
the safety and tolerability of this modality. Risks include those 
associated vvith brief anaesthesia, postictal confusion, and, 
more rarely, short-term memory difficulties. ECT is indicated 
when a rapid antidepressant response is needed, when drug 
therapies have fai led or when there is a history of good response 
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to Eel It is particularly effective in the treatment of delusional 
depression. H 
Prognosis 
The average age of the first episode of a major depression 
occurs in the mid-20s and although the first episode may occur 
at any time, from early childhood through to old age, a substantial 
proportion of people have their first depression in childhood or 
adolescence. I j It is generally thought that depression is usually 
a time-limited disorder lasting up to six months with complete 
recovery afterwards. However around 20% of patients remain 
depressed for 2 years or more. 
While around half of those affected by depression will 
have no further episodes, depressive illnesses, have a strong 
tendency for recurrence. At least 50% of people following their 
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Dr Arlene BONELLO MD DFM 
Tminee SpeCialist Family Medicille 
9. Amelican Psychiatric Association. Diagnostic and statistical manual of 
mental disorders. Wlshington DC: American PsychiatriC Association; 
199+. 
10. Anclrms, G. &jenkins, R. (Eds.) (1999). Management of Mental 
Disorders (UK edition, Vol. 1) S)'e1ne)': WHO Collaborating Centre 
for Mental Healrh anel Substance Misuse 
11. Goldberg et al; Psychiatry in Medical Practice 
12. BroWll Gw, Hanis 1 Copcland J R. Depression allelloss. Br. J. Psychiarry 
1977; 130:1-18 
13. Goldberg et al; Management of Depression in primary and secondary 
care; !\ational Clinical Practice guidelines by National Collaborating 
Centre for Mental Health 
14. Cornelius Katona and Marl' Robcrrson; (2003) Psychiatry at a Glance. 
15. Fal'a, M. & Kendler, K. (2000) Major depressil'C disorder. Neuron, 
28(2), 335-341 
16. Kupfer, Dj. (1991). Long-rerm rreatmenr of e1eprcssion.joulllal 
of Clinical Psychiatry, 52 (Suppl. 5), 28-34. 
17. Gib, D.E.,jarrctt , KB., Riggs , M.M. et aL (1989). Clinical predictors 
of rCCUlTence in depression. American joulllal of Psychiarry, 
146(6),76+-767. 
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Answers to Self-Assessment quiz: 
01 b 06 b 
02 
03 
04 
05 
a 
e 
e 
e 
07 abe 
08 abed 
09 abed 
010 ab d 
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